Rosuvastatin and progression of atherosclerosis

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 7, 2008, Pages 925-933

  Nicholls, Stephen J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Imaging; Rosuvastatin

Indexed keywords

AMLODIPINE; ATORVASTATIN; C REACTIVE PROTEIN; ENALAPRIL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTRAVASCULAR ULTRASOUND; LOW DRUG DOSE; NON INVASIVE MEASUREMENT; PRIMARY PREVENTION; CARDIOVASCULAR DISEASE; CORONARY BLOOD VESSEL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CORONARY VESSELS; DISEASE PROGRESSION; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONAMIDES;

EID: 52049089501     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.7.925     Document Type: Article

References (46)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinivastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
3. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
5. Sacks FM, Pfeffer MA, Moye LA et al.; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009 (1996).
6. Shepherd J, Cobbe SM, Ford I et al.; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307 (1995).
7. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437-2445 (2005).
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
9. Kapur NK. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev. Cardiovasc. Ther. 5, 161-175 (2007).
10. McKenney JM. Pharmacologic options for aggrossive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol. 96, 60E-66E (2005).
11. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160 (2003).
12. Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am. J. Cardiol. 82, 5M-11M (1998).
13. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
14. Ambrose JA, Tannenbaum MA, Alexopoulos D et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12, 56-62 (1988).
15. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 92, 2333-2342 (1995).
16. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432-1437 (1997).
17. Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am. J. Epidemiol. 146, 483-494 (1997).
18. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128, 262-269 (1998).
19. O'Leary DH, Polak JF, Kronmal RA Manolio TA, Burke GL, Wolfson SK Jr; Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med. 340, 14-22 (1999).
20. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35, 2902-2909 (2004).
21. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on Atherosclerosis Progression In Familial Hypercholesterotaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577-581 (2001).
22. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
23. Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297, 1344-1353 (2007).
24. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
25. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
26. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38 (2005).
27. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
28. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556-1565 (2006).
29. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297, 499-508 (2007).
30. Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117, 2458-2466 (2008).
31. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano, RC. Coronary artery calcium score combined with Framingham score fbr risk prediction in asymptomatic individuals. JAMA 291, 210-215 (2004).
32. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch. Intern. Med. 164, 1285-1292 (2004).
33. Shaw LJ, Raggi P, Schisterman E, Berman DS, Caltister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-muse mortality. Radiology 228, 826-833 (2003).
34. Achenbach S, Ropers D, Pohle K et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 106, 1077-1082 (2002).
35. Raggi P, Davidson M, Callister TQ et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 112, 563-571 (2005).
36. Schmermund A, Achenbach S, Budde T et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 113, 427-437 (2006).
37. Achenbach S, Ropers D, Pohle FK et al. Detection of coronary artery stenoses using multi-detector CT with 16×0.75 collimation and 375 ms rotation. Eur. Heart. J. 26, 1978-1986 (2005).
38. Salm LP, Bax JJ, Jukema JW et al. Comprehensive assessment of patients after coronary artery bypass graftirig by 16-detector-row computed tomography. Am. Heart J. 150, 775-781 (2005).
39. Worthley SG, Helft G, Fuster V et al. Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. Circulation 101, 2956-2961 (2000).
40. Fayad ZA, Nahar T, Fallon JT et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 101, 2503-2509 (2000).
41. Corti R, Fayad ZA, Fuster V et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104, 249-252 (2001).
42. Corti R, Fuster V, Fayad et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
43. Corti R, Fuster V, Fayad ZA et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 46, 106-112 (2005).
44. Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155, 584 e581-e588 (2008).
45. Kawasaki M, Sano K, Okubo M et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J. Am. Coll. Cardiol. 45, 1946-1953 (2005).
46. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteases, and cell death in human carotid plaques. Circulation 103, 926-933 (2001).